唐贝宁医药科技

Tangning Pharmaceutical Technology (formerly Tangbeining Pharmaceutical Technology) is a Chinese biopharmaceutical company focused on the research and development of traditional Chinese medicine (TCM) and modern botanical drugs for chronic diseases, particularly diabetes and its complications. The company's lead pipeline candidate, Guizhi Tangju Granules, is currently in Phase 2 clinical trials for the treatment of diabetic foot ulcers and diabetic nephropathy. Additionally, the company is developing Tangbeining Granules for diabetes complications. By combining traditional herbal medicine with modern biological research, the company aims to provide effective, multi-target therapeutic solutions for metabolic and microvascular disorders.